Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550159 | 0.79 | NLRP3 (0.44) | NLRP3ALDH1A1LMNAPOLB | |
| SCHEMBL22125852 | 0.76 | — | — | |
| SCHEMBL11205239 | 0.73 | NLRP3 (0.44) | NLRP3PDK1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL15700230 | 0.72 | NLRP3 (0.36) | NLRP3PDK1ALDH1A1HSD17B10 | |
| SCHEMBL21662453 | 0.70 | NLRP3 (0.34) | NLRP3PDK1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5013481 | 0.69 | — | — | |
| SCHEMBL10290385 | 0.69 | LMNA (0.64) | PDK1ALDH1A1LMNAPOLB | |
| SCHEMBL17269992 | 0.69 | LMNA (0.64) | PDK1ALDH1A1LMNAPOLB | |
| SCHEMBL118897 | 0.69 | LMNA (0.64) | PDK1ALDH1A1LMNAPOLB | |
| SCHEMBL1023407 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | claimed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | claimed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-7122693-B2 | Acetaldehyde acetal compounds, their synthesis, and uses thereof | SHIRE BIOCHEM INC. (CA) | 2006-10-17 | — | — | US | disclosed |
| US-7119202-B1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | GLAXO WELLCOME INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | disclosed |
| US-6897322-B2 | Method of producing 1-alkyl-3-aryl-5-difluoromethoxy-1H-pyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | BELLEAU BERNARD (CA) | 2004-12-16 | — | — | US | disclosed |
| US-20040059128-A1 | Method of producing 1-alkyl-3-aryl-5-difluoromethoxy-ih-pyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-6350753-B1 | 2-ACETOXYMETHYL-4-(THYMIN-1'-YL)-1,3,-DIOXOLANE; 2-BENZOYLOXYMETHYL-4-(CYTOSIN-1'-YL)-1,3-DIOXOLANE; ANTIVIRAL AGENTS, PARTICULARY FOR THE TREATMENT OF THE HIV INFECTIONS IN MAMMALS, ESPECIALLY HUMANS | BIOCHEM PHARMA INC. (CA) | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | NLRP3 1499/4885PDK1 994/4885ALDH1A1 848/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | NLRP3 1468/4885PDK1 986/4885ALDH1A1 911/4885 |
| US-20040059128-A1 | Method of producing 1-alkyl-3-aryl-5-difluoromethoxy-ih-pyrazoles | CYP2E1, CYP2F1, CYP1A1 | NLRP3 3178/4885PDK1 748/4885ALDH1A1 28/4885 |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | IFNAR1, ZC3HAV1, NUDT1 | NLRP3 1527/4885PDK1 1326/4885ALDH1A1 585/4885 |
| US-20040254201-A1 | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties | IFNAR1, ZC3HAV1, MAVS | NLRP3 1354/4885PDK1 1532/4885ALDH1A1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.